BeyondSpring Inc. (BYSI) - Quarterly EPS earnings growth
BeyondSpring Inc. is implementing eco-friendly waste disposal methods and protecting its developments with patents despite stringent FDA requirements. The quarterly EPS dynamics on the GURU.Markets chart illustrate the current trend, where 54.50 serves as the current value of the indicator. The application of an asset-light model and outsourced production allows BeyondSpring Inc. to effectively scale profits while minimizing the impact of fixed costs on R&D.
%20Year-over-year%20net%20earnings%20per%20share%20growth%20for%20the%20last%2012%20months&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_BYSI_-_BeyondSpring-Inc._-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "BeyondSpring Pharma (BYSI) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for BeyondSpring Inc.
- market value and analyst target forecast:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and liquidity details:
Debt to Equity BeyondSpring Inc.|BYSI - Long-Term Liabilities to Capital|Short-Term Debt to Capital BeyondSpring Inc.|BYSI - Company Total Indebtedness|Debt to Book Value BeyondSpring Pharma|BYSI - Long-Term Debt|Company Current Liabilities BeyondSpring|Quick Liquidity Indicator beyondspringpharma.com
- earnings and market multiples details:
BYSI - Profit After Payment of Taxes|Projected Future Earnings BeyondSpring Inc.|BYSI - Company Value to Net Income|Forward P/E Multiple BeyondSpring Pharma|BYSI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BeyondSpring Pharma|BYSI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BeyondSpring|BYSI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months beyondspringpharma.com|BYSI - Earnings per share trend in current year|Expected earnings per share growth for next year BeyondSpring Inc.
Fundamental company analysis:BeyondSpring, BYSI
To assess the long-term sustainability of BeyondSpring Inc. (BYSI), it is critical to analyze the quarterly earnings per share (EPS) growth rate, which mathematically captures the impact of inflationary costs and logistics on net margins. This indicator's trend reflects the efficiency of cross-platform management under strict regulatory oversight, allowing investors to weigh profit growth rates against the risks associated with new drug development.
Analysis of competing companies
Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BioAtla Corp BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology Holdings)|CTXR (citiuspharma.com) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com
